FUNDAMENTALS · Fundamentals · TW Healthcare

Apex Biotechnology (1733) Fundamentals 2026 — P/E 17.4x, Revenue Analysis | SniperIQ

Apex Biotechnology (1733) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT

.2B, trading at NT1.60 on the TAI. This SniperIQ fundamentals page covers Apex Biotechnology's valuation (P/E 17.4x, P/B 1.7x), profitability (net margin 9.6%), revenue (NT
.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
.2B
P/E (TTM)17.4x
Net Margin9.6%
Revenue (FY25)NT
.9B

Full research coverage

Frequently Asked Questions

What is Apex Biotechnology's market cap?

Apex Biotechnology (1733) has a market capitalization of approximately NT

.2B, trading at NT
1.60 on the TAI. Market cap moves with the live share price.

What is Apex Biotechnology's P/E ratio?

Apex Biotechnology's trailing twelve-month P/E ratio is 17.4x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Apex Biotechnology?

Apex Biotechnology runs a net profit margin of 9.6%, a gross margin of 28.6%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Apex Biotechnology generate?

Apex Biotechnology reported revenue of NT

.9B for fiscal year 2025, with net income of NT
63M and earnings per share (EPS) of 1.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Apex Biotechnology pay a dividend?

Apex Biotechnology offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Apex Biotechnology financially healthy?

Apex Biotechnology carries a debt-to-equity ratio of 0.09x and a current ratio of 3.14x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Apex Biotechnology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Apex Biotechnology (1733) the key facts are: market cap NT

.2B, P/E 17.4x, revenue NT
.9B, 52-week range 27-38.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Apex Biotechnology's full fundamentals live

Get Apex Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.